rjegse type a plus :	sign (+) trains trus ook	7	•	Amount for use through 10/31/2002 OM	B/81 (02-01) B 0651-0035	
Under the Paperwo	ork Reduction <u>Apt of 1995, no parso</u>	ons are required to respond to	U.S. Patent and a collection of info	Trademark Office; U.S. DEPARTMENT OF Common unless it displays a valid OMB control	COMMERCE	
	·	Appli ati n		09/585,817		
	A	Filing Date		June 1, 2000		
POWER OF AUTORNEY OR AUTHOR CATION OF AGENT			Inventor	Schenk, Dale B.		
				Prevention and Treatment of Amyloldogenic Disease		
AUTIL	ALIDITOR NO HOLI	Group Art U	nit	1647		
		Examiner N		Turner, Sharon L.		
U			cket Number	15270J-005910US		
		1 Attorney De				
I hereby app ☑ Practition OR		20350		Place Customer Number Bar Code Label here		
☐ Practition	er(s) named below:					
<u> </u>	Name		Regis	stration Number		
				•	[
L						
ſ						
-0 ===/or 4ff	tomey(s) or agent(s) to prose	cute the application ide	ntified above, ar	nd to transact all		
t ni seeniaud	he United Stales Patent and	Trademark Office conn	ected therewith.	:		
	ge the correspondence addre e-mentioned Customer Numl		ied application t	a;	-	
Practition	ers at Customer Number					
☐ Firm or Individua	d Name					
Address						
City		S	ate	ZIP		
Country						
Telephone			ax			
i am the:		<u></u>				
	ant/Inventor.					
	nee of record of the entire into	erest. See 37 CFR 3.7	1.			
	ent under 37 CFR 3.73(b) is					
		SNATURE of Applican		f Record		
Name	Kevin Insley, Vice President, Neuralab Limited					
Signature	Catabands					
Date						
NOTE: Sign:	atures of all the inventors o	r assignees of record	of the entire inte	erest or their representation (c) are	required.	
Submit multi	ple forms if more than one 1 forms are submitted.	sibilarnie is tedrilied*	SEE DEROW.			
	· · - · · · · · · · · · · · · · · · · ·					

Burden Hour Statement: This form is estimated to take 3 minutes to complete. Time will vary depending up in the heads of the individual case. Any Comments on the amount of time you are required to complete this form should be sent to the Chief Information of the Journal of time you are required to complete this form should be sent to the Chief Information of the Journal of Trademark Office. Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. JEND, TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3202741 v1

PM TTC-PA 650-326-2422

	Approved for use through 10/31/2002, OMB 0551-0031 Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE				
Under the convent Reduction Act of 1925, no persons are required to respond	to a cottection of information unless it displays a valid OMB control number. Attorney Docket No. 15270J-005910US				
A •	Attorney Docket No. 192703-00391003				
STATEMENT UNDER	37 CFR 3.73(b)				
plicant/Patent Owner: Dale B. Schenk	<u> </u>				
- Application of the second of	Issue Date: June 1, 2000				
Entitled: Prevention and Treatment of Arryloidogenic Disease					
Nguratab Limited , a corporation					
(Name of Assignee) (Type of Assignee	a, e.g., corporation, pertnership, university, government agenty, etc.)				
stales that it is:	·				
1, 🔲 the assignee of the entire right, title, and interest; or					
 an assignee of less than the entire right, title and interesting the extent (by, percentage) of its ownership interesting. 	erest.				
	_				
in the patent application/patent identified above by virtue of either					
A. An assignment from the Inventor(s) of the patent applicable was recorded in the United States Patent and Trademark	n/patent identified about the assignment Office at Reel Office at Reel				
which a copy thereof is attached.					
OR .					
B. A chain of title from the inventor(s), of the patent application	n/patent identified above, to the current assignee				
as shown below:	Special Control of Con				
1. From: Date B. Schenk To	:Etan Pharmaceuticals, Inc.				
The document was recorded in the United States Pa	ent and Trademark Office at				
Real 012230, Frame 0877, or for which a copy there	of is attached.				
2. From: Elan Pharmaceuticals, Inc. 1	o :Neuralab Limited				
The document was recorded in the United States Pa					
Reel <u>012230</u> , Frame <u>0885</u> , or for which a copy there	of is attached.				
3. From: Elan Pharmaceuticals, Inc.	o :Neuralab Limited (Nunc Pro Tunc)				
The document was recorded in the United States Pa					
Reel <u>012230,</u> Frame <u>0893</u> , or for which a copy there	of is attached.				
Additional documents in the chain of title are listed on a supplemental sheet.					
Copies of assignments or other documents in the chain of title are attached. (NOTE: A separate copy (i.e., the original assignment document or a true copy of the original document)					
must be submitted to Assignment Division in accordance wit recorded in the records of the USPTO. See MPEP 302.8]	n 37 CFR Part 3, if the assignment is to be				
The undersigned (whose title is supplied below) is authorized to	act on behalf of the assignee.				
FEMPUARY 28, 2002	Kevin insley				
Date	Typed or printed name				
· .	Cartania				
	Signature 1				
	Vice President				
	Tjile				

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3202744 v1